Andrew Peter O'Brien

Headquartered in New York City, Crystal Research Associates is an independent research company dedicated to increasing the visibility of innovative and growing private and public companies. They focus on companies demonstrating solid growth prospects, well-designed operating and growth strategies, an experienced and proven management team, command of a niche position in a large and expanding market, and a unique or innovative position or technology. The firm was founded in 2003

Part of US Patent Innovations LLC, US Medical Innovations LLC is a privately held FDA registered life science, biomedical and robotic device company based in Takoma Park, MD. US Medical Innovations is dedicated to expanding the boundaries of plasma medicine by pioneering new technologies for the development of state-of-the-art medical devices that advance patient outcomes and improve human lives. The company develops products for laparoscopic, robotic and cancer surgeries. The company was founded in 2009 by Jerome Canady and Kimberly Wiley, with Jerome Canady serving as CEO since then.

Cra Advisors LLC provides investment advisory services. The private company is based in New York. The American company was founded by Jeffrey J. Kraws. Jeffrey J. Kraws has been the CEO since incorporation.

Part of Delek Group Ltd., Phoenix Holdings Ltd. (US) is a company that provides financial services. The company is based in Austin, TX.

TopHat Capital LLC is a financial services firm that operates as an execution-based company. The private company is based in New York, NY. The company was founded by Jeffrey J. Kraws.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.